MADRIGAL PHARMACEUTICALS, INC.
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
A roundup of Tuesday Wall Street analyst actions included Deutsche Bank upgrading Palantir to Buy and keeping a $200 target, and Wells Fargo initiating APi Group at Overweight with a $53 target. Other calls covered CoreWeave, Micron, Walmart, Nike, Apple, and SK Hynix, with multiple price targets and rating changes ahead of earnings for some names.
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-63026earningspr.htm EX-99.1 Document Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year gro
Over the past 7 days, alphai's AI scored 2 news stories mentioning MDGL (MADRIGAL PHARMACEUTICALS, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent MDGL coverage spans financial news, insider activity and corporate actions.
In the last 30 days, MDGL insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($1.4M). The most active reporter was Sibold William John, President and CEO, with 10 filings.
Upgrade suggests a valuation reset opportunity if delays are perceived as less severe than priced.
Upgrade can support biotech momentum, but the article lacks the specific new clinical or regulatory datapoint.
The 8-K provides fresh, decision-relevant operating and financial datapoints plus pipeline progress that can move near-term expectations for Rezdiffra demand and cash runway.
Insider selling is a sentiment signal, but this specific Form 4 does not disclose new fundamentals or guidance.
Inducement awards are typically modest dilution/overhang but can signal hiring and ongoing incentive alignment; no direct operational or clinical catalyst is disclosed.
alphai scores every news story that mentions MDGL with an AI model for sentiment and relevance, and aggregates insider trades from MADRIGAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readA roundup of Tuesday Wall Street analyst actions included Deutsche Bank upgrading Palantir to Buy and keeping a $200 target, and Wells Fargo initiating APi Group at Overweight with a $53 target. Other calls covered CoreWeave, Micron, Walmart, Nike, Apple, and SK Hynix, with multiple price targets and rating changes ahead of earnings for some names.
6 min readMADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-63026earningspr.htm EX-99.1 Document Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates • Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year gro
6 min readSibold William John (President and CEO) sold 2,500 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $547.30 ($542.75–$555.05, $1.37M total) across 10 trades on 2026-07-20.
2 min readMadrigal Pharmaceuticals (NASDAQ:MDGL) said it granted equity inducement awards on July 1, 2026 to seven new non-executive employees under its 2025 Inducement Plan. Awards total 604 options and 2,952 time-based RSUs; options exercise price is $514.39/share and vest quarterly after a 1-year cliff. RSUs vest in four annual installments.
2 min readSuzhou Ribo Life Science (06938.HK) and subsidiary Ribocure, with Madrigal Pharmaceuticals (NASDAQ: MDGL), said they reached the first candidate-drug nomination milestone in their siRNA partnership for metabolic dysfunction-associated steatohepatitis (MASH). The companies plan to start IND-enabling studies to support upcoming clinical trials, covering multiple preclinical assets.
3 min readMADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 tm2617490d2_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 MADRIGAL PHARMACEUTICALS, INC. 2026 STOCK PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Madrigal Pharmaceuticals 2026 Stock Plan (as amended from time to time, the “ Plan ”). The pur
3 min readSoergel David (Chief Medical Officer) sold 1,042 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $495.74 ($0.52M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has granted equity awards to seven new non-executive employees as inducement awards under its 2025 Inducement Plan. These awards, consisting of 1,739 time-based restricted stock units, will vest in four equal annual installments, contingent on continued employment. The grants were made to attract and incentivize the new hires at the biopharmaceutical company, which focuses on developing treatments for a liver disease called metabolic dysfunction-associated steatohepatitis.
2 min readMadrigal Pharmaceuticals reported strong Q4 revenue driven by its new MASH therapy, Rezdiffra, which surpassed expectations and gained analyst confidence. Despite still operating at a loss due to high commercialization costs, the early traction of Rezdiffra and analyst optimism suggest a credible path to scaling the franchise. Investors should monitor prescription trends, payer coverage, and operating expenses, acknowledging risks from rising discounts and competition from GLP-1 therapies.
3 min read
